Who
Paul J. Clancy
Director
Company insider
Files Form 4 as: Director, Incyte; Director, Sionna Therapeutics; Director, Exact Sciences; Director, Xilio Therapeutics; Director, Agios Pharmaceuticals; EVP, Chief Financial Officer, Alexion Pharmaceuticals; Executive VP and CFO, Biogen.
In numbers
- Trades disclosed
- 333
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $52.8M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 4 Sep 2007
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $25K203 at $121.35 | filing |
| 30 Jun 2026filed 2 Jul 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $29K252 at $113.36 | filing |
| 30 Jun 2026filed 2 Jul 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $29K252 at $113.36 | filing |
| 17 Jun 2026filed 18 Jun 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,340 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,340 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $1.3M15,000 at $84.53 | filing |
| 19 May 2026filed 21 May 2026 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $1.4M15,000 at $94.93 | filing |
| 19 May 2026filed 21 May 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $1.3M15,000 at $84.53 | filing |
| 19 May 2026filed 21 May 2026 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $1.4M15,000 at $94.93 | filing |
| 31 Mar 2026filed 2 Apr 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $25K265 at $94.12 | filing |
| 31 Mar 2026filed 2 Apr 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | $25K265 at $94.12 | filing |
| 23 Mar 2026filed 23 Mar 2026 | Exact SciencesDiagnostics & Labs | SEC FORM 4 Code D | —20,640 | filing |
| 23 Mar 2026filed 23 Mar 2026 | Exact SciencesDiagnostics & Labs | SEC FORM 4 Code D | —5,398 | filing |
| 23 Mar 2026filed 23 Mar 2026 | Exact Sciences | SEC FORM 4 Code D | —20,640 | filing |
News
Incyte (NASDAQ:INCY) & Agios Pharmaceuticals (NASDAQ:AGIO) Critical ContrastINCY · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Paul J. Clancy; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.